Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study-Reference-Cited by-同舟云学术

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Published:2021-08 Issue:8 Volume:9 Page:829-839
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Shi Yuankai,Hu Xingsheng,Zhang Shucai,Lv Dongqing,Wu Lin,Yu Qitao,Zhang Yiping,Liu Li,Wang Xiang,Cheng Ying,Ma Zhiyong,Niu Hongrui,Wang Dong,Feng Jifeng,Huang Cheng,Liu Chunling,Zhao Hui,Li Jingzhang,Zhang Xiaodong,Jiang Yong,Gu Chuan

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms;Yamaoka;Int J Mol Sci,2017

3. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology—mainland China subset analysis of the PIONEER study;Shi;PLoS One,2015

4. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J Thorac Oncol,2014

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib;Toxicology;2024-09

2. Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial;Lung Cancer;2024-09

3. Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer;JAMA Oncology;2024-07-01

4. EGFR kinase domain duplication in lung adenocarcinoma with systemic and intracranial response to a double-dose of furmonertinib: a case report and literature review;Frontiers in Oncology;2024-06-21

5. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents;Current Medicinal Chemistry;2024-06-10